Medico-economic Evaluation of the Therapeutic Drug Monitoring of Anti-TNF-α Agents in Inflammatory Bowel Diseases (ATAIM)

Clinical Trial ID NCT02508012

PubWeight™ 0.00^‹?›

🔗 Visit the ClinicalTrials.gov page for NCT02508012

Top papers

Rank	Title	Journal	Year	PubWeight™‹?›
1	Influence of immunogenicity on the long-term efficacy of infliximab in Crohn's disease.	N Engl J Med	2003	8.49
2	Individualised therapy is more cost-effective than dose intensification in patients with Crohn's disease who lose response to anti-TNF treatment: a randomised, controlled trial.	Gut	2013	3.49
3	Development of antidrug antibodies against adalimumab and association with disease activity and treatment failure during long-term follow-up.	JAMA	2011	2.73
4	Clinical response to adalimumab: relationship to anti-adalimumab antibodies and serum adalimumab concentrations in rheumatoid arthritis.	Ann Rheum Dis	2007	2.67
5	The immunogenic part of infliximab is the F(ab')2, but measuring antibodies to the intact infliximab molecule is more clinically useful.	Gut	2010	2.61
6	Clinical utility of measuring infliximab and human anti-chimeric antibody concentrations in patients with inflammatory bowel disease.	Am J Gastroenterol	2010	2.55
7	A test-based strategy is more cost effective than empiric dose escalation for patients with Crohn's disease who lose responsiveness to infliximab.	Clin Gastroenterol Hepatol	2013	2.31
8	Influence of trough serum levels and immunogenicity on long-term outcome of adalimumab therapy in Crohn's disease.	Gastroenterology	2009	2.00
9	Extent and clinical consequences of antibody formation against adalimumab in patients with plaque psoriasis.	Arch Dermatol	2010	1.77
10	Severe infusion reactions to infliximab: aetiology, immunogenicity and risk factors in patients with inflammatory bowel disease.	Aliment Pharmacol Ther	2011	1.70
11	Impact of antibodies to infliximab on clinical outcomes and serum infliximab levels in patients with inflammatory bowel disease (IBD): a meta-analysis.	Am J Gastroenterol	2012	1.66
12	Antibody response to infliximab and its impact on pharmacokinetics can be transient.	Am J Gastroenterol	2013	1.61
13	Therapeutic drug monitoring of infliximab and mucosal healing in inflammatory bowel disease: a prospective study.	Inflamm Bowel Dis	2013	1.49
14	Association between pharmacokinetics of adalimumab and mucosal healing in patients with inflammatory bowel diseases.	Clin Gastroenterol Hepatol	2013	1.26
15	Decreased clinical response to adalimumab in ankylosing spondylitis is associated with antibody formation.	Ann Rheum Dis	2009	1.04